Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability.
- Exploring Takeda's Template For Sustainable Steam Generation
- Transforming Computer System Validation In The Life Sciences Industry
- Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 3: Building A Compliant Program
- An Open-Source Modeling Tool For Suspended Continuous Lyophilization
- Mapping Early-Phase Supply Chain Bottlenecks That Doom Pipelines
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 2: Objective Measurement Tools
GUEST COLUMNISTS
-
Exploring Takeda's Template For Sustainable Steam Generation
Takeda designed a model for delivering steam at 11 bar and up to 184 degrees using natural refrigerant and waste heat at one of its largest production sites.
-
Transforming Computer System Validation In The Life Sciences Industry
Regulators acknowledge how traditional CSV methods fail to meet modern demands for speed and flexibility. The scene is changing in favor of smarter, leaner validation.
-
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis
Since every sponsor–CDMO relationship can have widely different scopes, requirements, and procedures, this article focuses on the basic principles for analyzing and managing the risks of not achieving the relationship’s objectives.
-
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 3: Building A Compliant Program
In this third and final article of this series, let's take a closer look at what a well-constructed Annex 1-compliant program looks like at each stage, from gap assessment through governance.
-
An Open-Source Modeling Tool For Suspended Continuous Lyophilization
Building on a continuous suspended-vial lyophilization workflow, process developers can model critical variables before doing physical experiments.
-
Mapping Early-Phase Supply Chain Bottlenecks That Doom Pipelines
Many sponsors miscast preclinical development as an unglamorous step between discovery and the clinic. Here's how the consequences may lead to irrevocable losses.
-
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 2: Objective Measurement Tools
Let's examine the objective measurement tools that directly address each of the gaps between Annex 1 expectations and what drug manufacturing facilities can currently demonstrate in practice.
BIOSIMILAR WHITE PAPERS
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Process Intensification And Other Ways To Adapt To Changing Needs7/20/2026
As biologics manufacturing evolves, gain insight into why productivity depends on smarter investments, flexible production strategies, and supplier support that can address shifting modalities.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Bio-Based Polymers Towards Net Zero In Single-Use Bioprocessing6/13/2025
Decarbonizing healthcare and pharmaceuticals is vital to meet climate goals and safeguard public health. Learn why these energy-intensive sectors must act swiftly to reduce emissions and navigate complex global supply chains.
BIOSIMILAR APP NOTES & CASE STUDIES
- Microbial Integrity Of Sampling Systems After Multiple Actuations
- Protect Your Columns And Your Peaks
- Evaluation Of Extractables And Physical Compatibility Of The MobiusĀ® ADC Reactor Single-Use Components For ADC Manufacturing
- Integrated Services For Cell Line Preparation And Storage
- Enhanced Flow Kit Performance With Leak And PUPSIT Testing
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Biocon Announces U.S. Commercial Launch of Yesafili, A Biosimilar To Regeneron's Eylea 2 mg
- Fresenius Announces FDA Approval Of Rituximab Biosimilar For The U.S. Market
- Polpharma Biologics Announces FDA And EMA Acceptance For Review Of PB016 Vedolizumab Biosimilar Candidate
- Meitheal Pharmaceuticals Announces FDA Approval Of Garzulys (insulin aspart-fsan) Injection
- HSCA Applauds House Energy And Commerce Commitee And Senate HELP Commitee For Advancing Bipartisan Biosimilars Legislation That Will Help Increase Access To Safe Medications
- Alvotech Announces Successful Closure Of FDA Inspection Of Manufacturing Facility
- Mabwell Established A Licensing And Commercialization Agreement Of Aflibercept Biosimilar For GCC Market
- The Biosimilars Council And AAM Applaud Senate Markup And Committee Passage Of The Expedited Access To Biosimilars Act
NEWSLETTER ARCHIVE
- 07.30.26 -- FDA Explains How To Respond To Form 483 Observations
- 07.23.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line
- 07.16.26 -- Is Your AI Model Trustworthy & Credible In GMP Processes
- 07.09.26 -- Affinity Membranes Are Moving Closer To Commercial Reality
- 07.02.26 -- What Reliance, Annex 1, And AI Mean For The Future Of GMP